Literature DB >> 31514655

Departures from Cost-Effectiveness Recommendations: The Impact of Health System Constraints on Priority Setting.

Katharina Hauck1, Ranjeeta Thomas1, Peter C Smith2.   

Abstract

Abstract-The methods and application of cost-effectiveness analysis have reached an advanced stage of development. Many decision makers consider cost-effectiveness analysis (CEA) to be a valid and feasible approach toward setting health priorities, and it has been extensively applied in evaluating interventions and developing evidence-based clinical guidelines. However, the recommendations arising from cost-effectiveness analysis are often not implemented as intended. A fundamental reason for the failure to implement is that CEA assumes a single constraint, in the form of the budget constraint, whereas in reality decision makers may be faced with numerous other constraints. The objective of this article is to develop a typology of constraints that may act as barriers to implementation of cost-effectiveness recommendations. Six categories of constraints are considered: the design of the health system; costs of implementing change; system interactions between interventions; uncertainty in estimates of costs and benefits; weak governance; and political constraints. Where possible-and if applicable-for each class of constraint, the article discusses ways in which these constraints can be taken into account by a decision maker wishing to pursue the principles of cost-effectiveness.

Entities:  

Keywords:  cost-effectiveness analysis; decision making; health technology assessment; implementation; priority setting

Year:  2016        PMID: 31514655     DOI: 10.1080/23288604.2015.1124170

Source DB:  PubMed          Journal:  Health Syst Reform        ISSN: 2328-8620


  2 in total

Review 1.  Mapping the evidence on health equity considerations in economic evaluations of health interventions: a scoping review protocol.

Authors:  Hafizah Besar Sa'aid; Sharon Mathew; Marina Richardson; Joanna M Bielecki; Beate Sander
Journal:  Syst Rev       Date:  2020-01-08

2.  Cost-effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole or letrozole as monotherapy in first-line treatment of postmenopausal women with HR+/HER2- locally advanced or metastatic breast cancer: a Brazilian private payer perspective.

Authors:  Anna Maria Buehler; Gabriela Castilho; Pierre-Alexandre Dionne; Stephen Stefani
Journal:  Ther Adv Med Oncol       Date:  2021-04-16       Impact factor: 8.168

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.